Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. - Test2 - elhamkhani - TriplyDB

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

http://www.wikidata.org/entity/Q39926027

about

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.Aberrant expression of ALK and EZH2 in Merkel cell carcinoma Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA.A perspective on the impact of radiation therapy on the immune rheostat.Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay.Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.Merkel Cell Carcinoma Therapeutic Update.Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.The Emerging Role of TRAF7 in Tumor Development.Targeting neoantigens to augment antitumour immunity.Merkel cell polyomavirus and Merkel cell carcinoma.Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Higher Expression of Activation-induced Cytidine Deaminase Is Significantly Associated with Merkel Cell Polyomavirus-negative Merkel Cell Carcinomas Metastatic Merkel cell carcinoma response to nivolumab.Merkel Cell Polyomavirus: A New DNA Virus Associated with Human Cancer.Genomic analysis of atypical fibroxanthoma.Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.Merkel cell carcinoma patients presenting without a primary lesion have elevated markers of immunity, higher tumor mutation burden and improved survival.Merkel cell carcinoma in the age of immunotherapy: Facts and hopes.Are there multiple cells of origin of Merkel cell carcinoma?Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.Avelumab and other recent advances in Merkel cell carcinoma.PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.A Monoclonal Antibody to SV40 Large T Antigen (PAb416) Does Not Label Merkel Cell Carcinoma.MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus.Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.

P2860

Q27853379-D55988E6-ADF0-48AD-BDBD-CA42E24CD5BB Q36328692-FD8E5295-7F87-467F-82C2-CE6A3B13450F Q37117867-534F32F3-4325-4A79-9887-BAAFEFD25E0F Q38378516-091E0545-E2A4-4BB7-BF97-8F18FD29192F Q38611235-FDE4431C-53D6-4433-8AE9-C4CDA91A01FA Q38671851-8EEB799C-33C5-424F-8723-D5AE5987AB59 Q38679488-986DC38A-444F-4C27-BE85-3C6F5D005B63 Q38729084-336FD656-F3E3-46E1-BDCE-BFA4B44507F4 Q38738614-D7DBA23E-50B6-4780-95B0-C87832B6D917 Q38855013-A53203C5-A18A-42AE-8A54-DDA48D55ECBE Q38855025-2C30C835-260A-466C-923A-5BD0E96AF7D2 Q38868829-FDA45E12-46AB-4324-A84B-E6A74FB09130 Q38887303-F157289A-363A-4C5C-93F1-4327F179FE20 Q38904371-C4E33791-51A8-4CF6-A60E-DC84A3903A2C Q38997320-0AE46C3C-B53A-4D80-BA54-E072F164BA8A Q39149196-0EB31EDB-8A4D-4470-BEEA-82A86BF2E2C8 Q40046580-A11E2C8C-861B-4A0E-97A6-868BCAFAE3CB Q40100093-1C5B1478-2124-4372-ACB1-DCB9A80110C8 Q40245609-B3E289F6-32DD-4B2D-BF78-15BEC774B808 Q40463395-106C6DFB-B46C-473F-A3AF-0A30A0AA81A7 Q41133627-29C2BDB3-DEB3-471C-A345-CBBC7ED79E96 Q41681717-17CA199E-E569-4C40-81FF-822BE0C84613 Q42368667-804D357F-01B6-46E5-884B-C9D3AFDB68F4 Q45325990-95A9B372-D0F7-4B0F-BD08-FDFC50233553 Q46176867-5670EB13-C836-4441-9ECC-1B6815B9DA67 Q47114351-9C680856-9771-44C7-A873-D6564AA6CDFE Q47300122-2065084E-75E3-4F5A-A29F-E0F10A57C4C1 Q47348356-7B7DA8FD-4BD8-4B2E-B597-370AF9B7ACFB Q47555708-099CBDC9-A990-4DA5-A498-ACD3CD10FC71 Q47571383-54743793-5A7B-4D8E-896A-7A0CB65D0F16 Q47584286-DC2B8AC8-8316-43E8-89E3-CCAA4F478C3B Q47658993-D3C7B56D-0945-4233-9735-BF52D0C39B8F Q47915808-BA382B6A-0A4D-4E39-B062-8214387E5A68 Q49664880-22B1BC87-25AA-48C9-961E-75240D4698DD Q50060650-10399ECA-05CE-470A-863E-687EF4852BD5 Q50071669-5D6F82B5-EF80-46E3-A683-4C5F1CD41DC9 Q51061357-2FF52EE6-14C2-4354-8DFE-48BE0B8AEB28 Q51751201-0131C3BA-C652-4D08-92E8-9806DA6344E1 Q52804789-1CC33A37-EF15-4790-99C3-1B7559C89588 Q53358653-977419E1-602C-48AB-AC8A-0EFAD3C1BE86

P2860

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

http://www.wikidata.org/entity/Q39926027

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Mutational landscape of MCPyV- ...... mplications for immunotherapy.

@en

Mutational landscape of MCPyV- ...... mplications for immunotherapy.

@nl

type

label

Mutational landscape of MCPyV- ...... mplications for immunotherapy.

@en

Mutational landscape of MCPyV- ...... mplications for immunotherapy.

@nl

prefLabel

Mutational landscape of MCPyV- ...... mplications for immunotherapy.

@en

Mutational landscape of MCPyV- ...... mplications for immunotherapy.

@nl

P1433

Q39926027-4FD0FD1C-9EA9-4C50-A8E7-8DD997D5BA61

P1476

Q39926027-C9D37DAB-9588-43BE-A6F9-DF6FF3194A5B

P2093

Q39926027-31A94EDA-0FC9-4E73-9550-6FA0C29528CC

Q39926027-3513B1FB-5F0E-4F67-AFEF-A717C82A49DC

Q39926027-4AB4178D-349B-4617-A55C-B67AA20EF550

Q39926027-74A1421B-AAA0-42EE-83F3-FB4CBFBBBB55

Q39926027-9D2D2C01-AA52-4013-A0ED-2855A20F4113

Q39926027-A359355D-09AE-4D58-9E47-2D8FBB9E5607

Q39926027-A8CCFE5B-DA15-467F-BCC5-C811E99FF9C8

Q39926027-C472C0CA-3897-411A-AF60-6D5D90495C7D

Q39926027-CBF90807-94A2-4FF0-8D14-C08F7B295740

Q39926027-D86F0285-45F8-432C-AA27-3EE64E38052C

P2860

Q39926027-0493C7E7-9776-4C7D-9E39-8652C685EB63

Q39926027-06CC509D-10B1-486D-9DA2-B9611FAF5A3F

Q39926027-06E4634F-971E-484D-9964-3EAE58F27121

Q39926027-08422FF9-00DB-4E57-B95E-1C9D121B51B9

Q39926027-0FF29D6A-BDF7-40D6-9B7B-FF503A2F839E

Q39926027-17611517-6ABE-42A0-B95C-CDEF59116F16

Q39926027-231734E0-0C21-478E-A4C4-13BA38C710B4

Q39926027-29A0B420-53F9-493B-A6BB-7907C7BE6FF6

Q39926027-2F1A179B-D186-4AEA-9BF7-3B07C992FD8F

Q39926027-3B235001-116E-4A51-B6C2-C2E6913C48DF

P304

Q39926027-7B7B9A38-A771-4CAD-A0F8-4AA9CC017851

P31

Q39926027-AC6B369E-61F4-409B-81B0-54EB1CDE9B0B

P356

Q39926027-0A9B099A-5029-4682-AC37-95FE9AF78BFA

P407

Q39926027-7411B276-F6D4-49B4-93ED-ACE0B2BB3672

P433

Q39926027-1C82FC84-EE70-400D-9C6B-B5495C319A74

P478

Q39926027-0CB1E1A9-3939-421F-9C35-6B7B494DEFA9

P50

Q39926027-180F42C4-C3DC-4C3B-8EBE-997C8E06D3C7

Q39926027-C67002D9-E7AF-42CC-98DD-F6F8C5164C55

Q39926027-E2F90E55-0363-4AFD-B0F3-69703C00C0D7

P577

Q39926027-64FB5FBE-8D2B-443B-B275-05615DBE17E9

P5875

Q39926027-BD73F90B-BD01-48E3-905F-3B5D797AF27C

P698

Q39926027-6A5B0BEB-966D-4D82-89A3-EE6960287EB8

P921

Q39926027-72020476-C31C-49E3-A48C-091248201302

P932

Q39926027-F985307F-DBB5-44F9-98D1-99E5A6C1DC20

P356

ONCOTARGET.6494

P1433

P1476

Mutational landscape of MCPyV- ...... implications for immunotherapy

@en

P2093

Astrid Blom

http://www.w3.org/2001/XMLSchema#string

Gerald Goh

http://www.w3.org/2001/XMLSchema#string

Jonathan Levinsohn

http://www.w3.org/2001/XMLSchema#string

Krista Stafstrom

http://www.w3.org/2001/XMLSchema#string

Lola Yelistratova

http://www.w3.org/2001/XMLSchema#string

Paul Nghiem

http://www.w3.org/2001/XMLSchema#string

Richard P Lifton

http://www.w3.org/2001/XMLSchema#string

Ryan Doumani

http://www.w3.org/2001/XMLSchema#string

Timothy A Chan

http://www.w3.org/2001/XMLSchema#string

Trent Walradt

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator

T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus

Clonal integration of a polyomavirus in human Merkel cell carcinoma

Merkel cell carcinoma: changing incidence trends

Mutational landscape and significance across 12 major cancer types

Discovery and saturation analysis of cancer genes across 21 tumour types

Signatures of mutational processes in human cancer

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

P304

3403-3415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.6494

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286965959

http://www.w3.org/2001/XMLSchema#string

P698

26655088

http://www.w3.org/2001/XMLSchema#string

P921

P932

4823115

http://www.w3.org/2001/XMLSchema#string